RxDoctor Payments DataLook up a doctor →

Omotola Hope, MD

Clinical Neurophysiology · Houston, TXNPI 1477649184

Payments from drug & device makers

$83,125in general payments, 2019–2025

Across 950 payments — averaging $87.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$47K
  • Eisai Inc.$21K
  • AbbVie$3K
  • UCB, Inc.$2K
  • Novartis$989
  • Pfizer$886
  • plus $9K from 53 others

What the payments were for

  • Speaking & faculty fees$41,30066%
  • Travel & lodging$1,9183%
  • Food & beverage$19,65531%
  • Education$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.100$46,652
Eisai Inc.24$20,811
AbbVie(2 entities)197$3,235
UCB, Inc.92$1,918
Novartis63$989
Pfizer69$886
Neurocrine Biosciences, Inc.32$854
EMD Serono, Inc.36$666
Abbott22$518
Biogen23$518
Acadia Pharmaceuticals Inc25$515
AstraZeneca(2 entities)13$452
Lilly USA, LLC25$447
Takeda Pharmaceuticals U.S.A., Inc.15$344
Lundbeck LLC15$302
Amgen12$267
Sunovion Pharmaceuticals Inc.17$263
Amneal Pharmaceuticals LLC15$221
Greenwich Biosciences, Inc.5$212
Genentech USA, Inc.10$200
Harmony Biosciences LLC9$186
Biohaven Pharmaceutical Holding Company Ltd.16$181
Argenx US, Inc.6$174
Teva Pharmaceuticals USA, Inc.9$171
Biohaven Pharmaceuticals, Inc.5$165
Merz Pharmaceuticals, LLC7$154
Averitas Pharma Inc.2$138
Grifols USA, LLC6$138
Avadel CNS Pharmaceuticals, LLC2$137
Sanofi5$116
Neurelis, Inc.4$99
Neuropace, Inc.5$99
Jazz Pharmaceuticals Inc.4$97
Aquestive Therapeutics, Inc.5$92
Sumitomo Pharma America, Inc.11$91
Boston Scientific2$82
Monteris Medical Corporation1$70
Tanabe Pharma America, Inc.4$56
Azurity Pharmaceuticals, Inc.3$52
Kyowa Kirin, Inc.2$51
Catalyst Pharmaceuticals, Inc.2$43
Almatica Pharma LLC2$41
Supernus Pharmaceuticals, Inc.2$41
Livanova USA, Inc.2$39
Aucta Pharmaceuticals, Inc.7$39
Avanir Pharmaceuticals, Inc.2$35
Acorda Therapeutics, Inc2$34
Johnson & Johnson(2 entities)2$33
GRT US Holding, Inc.1$28
Medtronic1$28
Microtransponder, Inc.1$22
Integra Lifesciences Corporation1$22
Corium, LLC1$19
Mallinckrodt Hospital Products Inc.1$16
Impel Pharmaceuticals Inc.1$15
Arbor Pharmaceuticals, Inc.1$14
Avion Pharmaceuticals1$13
Alnylam Pharmaceuticals Inc.1$13
Insightec,inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,125 in reported general payments places this provider in the 85th percentile of 50 clinical neurophysiology providers in Texas.

See all clinical neurophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$92,289
Medicare patients
402
Services billed
3,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$85,690
EpidiolexCannabidiol (Cbd)24$84,650
Nurtec OdtRimegepant Sulfate47$80,359
AptiomEslicarbazepine Acetate12$72,658
XcopriCenobamate49$69,104
KeppraLevetiracetam18$48,865
Emgality PenGalcanezumab-Gnlm42$38,177
Lacosamide235$38,141
Aimovig AutoinjectorErenumab-Aooe32$32,474
FycompaPerampanel25$30,788
VimpatLacosamide24$29,107
UbrelvyUbrogepant21$28,769
Levetiracetam504$24,066
LamictalLamotrigine12$18,998
Clobazam45$13,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$854$85,69011 claims
PfizerNurtec Odt$886$80,35947 claims
Sunovion Pharmaceuticals Inc.Aptiom$263$72,65812 claims
SK Life Science, Inc.Xcopri$46,652$69,10449 claims
Eisai Inc.Fycompa$20,811$30,78825 claims
UCB, Inc.Vimpat$1,918$29,10724 claims
AbbVieUbrelvy$3,235$28,76921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 50 clinical neurophysiology providers in Texas.

Other clinical neurophysiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →